• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Reata Announces Top-Line Data from the Dose-Escalation Cohorts of the Phase 2 Motor Study

    Gabrielle Lakusta
    Mar. 02, 2018 09:26AM PST
    Pharmaceutical Investing

    Reata Pharmaceuticals (Nasdaq:RETA) a clinical-stage biopharmaceutical company, announced top-line data from the dose-escalation cohorts of the Phase 2 MOTOR trial of omaveloxolone for the treatment of patients with mitochondrial myopathies.  This 12-week, exploratory, dose-ranging trial enrolled 53 patients across six dose levels.  The purpose of the first-in-patient MOTOR trial was to evaluate initial safety, efficacy, …

    Reata Pharmaceuticals (Nasdaq:RETA) a clinical-stage biopharmaceutical company, announced top-line data from the dose-escalation cohorts of the Phase 2 MOTOR trial of omaveloxolone for the treatment of patients with mitochondrial myopathies.  This 12-week, exploratory, dose-ranging trial enrolled 53 patients across six dose levels.  The purpose of the first-in-patient MOTOR trial was to evaluate initial safety, efficacy, pharmacokinetics, and pharmacodynamics of omaveloxolone in this patient population.

    As quoted in the press release:

    The sample size of six to ten patients randomized to omaveloxolone and two to three randomized to placebo for safety controls at each dose level was based upon a traditional dose-escalation design.  The small number of patients at each dose was not expected to fully characterize safety, efficacy, or pharmacodynamics, but rather to inform the data safety monitoring board and Reata of the appropriate dose to select for future study.  The optimal dose of omaveloxolone associated with robust Nrf2 induction and improvement in markers of mitochondrial function was determined to be 160 mg.  At this dose, significant, placebo-corrected improvements were noted in Nrf2 biomarkers.

    Click here to read the full press release.

    pharmaceutical investingclinical-stage biopharmaceuticalclinical-stage biopharmaceutical company
    The Conversation (0)

    Go Deeper

    AI Powered
    A hand holding a double helix.

    Top 5 NASDAQ Genetics Stocks (Updated December 2023)

    Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×